UPDATE OF CARTITUDE-1: A PHASE 1B/2 STUDY OF JNJ-68284528 (JNJ-4528), A B-CELL MATURATION ANTIGEN (BCMA)-DIRECTED CHIMERIC ANTIGEN RECEPTOR T (CAR-T) CELL THERAPY, IN RELAPSED/REFRACTORY MULTIPLE MYELOMA (MM)

UPDATE OF CARTITUDE-1: A PHASE 1B/2 STUDY OF JNJ-68284528 (JNJ-4528), A B-CELL MATURATION ANTIGEN (BCMA)-DIRECTED CHIMERIC ANTIGEN RECEPTOR T (CAR-T) CELL THERAPY, IN RELAPSED/REFRACTORY MULTIPLE MYELOMA (MM)

Bibliographic Details
Main Authors:	J.G. Berdeja, D. Madduri, S.Z. Usmani, I. Singh, E. Zudaire, T.M. Yeh, A.J. Allred, Y. Olyslager, A. Banerjee, J.D. Goldberg, J. Schecter, D. Geng, X. Wu, M.J. Carrasco-Alfonso, S. Rizvi, F. Fan, A. Jakubowiak, S. Jagannath
Format:	Article
Language:	English
Published:	Elsevier 2020-11-01
Series:	Hematology, Transfusion and Cell Therapy
Online Access:	http://www.sciencedirect.com/science/article/pii/S2531137920307525

Similar Items

UPDATED RESULTS FROM THE CARTITUDE-1 STUDY OF CILTACABTAGENE AUTOLEUCEL, A B-CELL MATURATION ANTIGEN–DIRECTED CHIMERIC ANTIGEN RECEPTOR T CELL THERAPY, IN RELAPSED/REFRACTORY MULTIPLE MYELOMA
by: SZ Usmani, et al.
Published: (2021-10-01)

P961: CILTACABTAGENE AUTOLEUCEL, A BCMA-DIRECTED CAR-T CELL THERAPY, IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA: 2-YEAR POST LPI RESULTS FROM THE PHASE 1B/2 CARTITUDE-1 STUDY
by: Y. Lin, et al.
Published: (2022-06-01)

Preclinical and clinical characterization of the RORγt inhibitor JNJ-61803534
by: Xiaohua Xue, et al.
Published: (2021-05-01)

S202: CARTITUDE-1 FINAL RESULTS: PHASE 1B/2 STUDY OF CILTACABTAGENE AUTOLEUCEL IN HEAVILY PRETREATED PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA
by: Nikhil Munshi, et al.
Published: (2023-08-01)

B-cell maturation antigen (BCMA) in multiple myeloma: the new frontier of targeted therapies
by: Larysa Sanchez, et al.
Published: (2021-01-01)

B09 CARTITUDE-2 COHORT B 18-MONTH FOLLOW-UP: CILTACABTAGENE AUTOLEUCEL (CILTA-CEL), A BCMA-DIRECTED CAR-T CELL THERAPY, IN PATIENTS WITH MULTIPLE MYELOMA (MM) AND EARLY RELAPSE AFTER INITIAL THERAPY
by: S. Zweegman, et al.
Published: (2023-05-01)

Author Correction: Preclinical and clinical characterization of the RORγt inhibitor JNJ-61803534
by: Xiaohua Xue, et al.
Published: (2022-04-01)

CSF1R inhibitor JNJ-40346527 attenuates microglial proliferation and neurodegeneration in P301S mice
by: Mancuso, R, et al.
Published: (2019)

B07: SAFETY AND EFFICACY OF CILTACABTAGENE AUTOLEUCEL, A CHIMERIC ANTIGEN RECEPTOR T-CELL THERAPY DIRECTED AGAINST B-CELL MATURATION ANTIGEN IN PATIENTS WITH MULTIPLE MYELOMA AND EARLY RELAPSE AFTER INITIAL THERAPY: CARTITUDE-2 RESULTS
by: NWCJ van de Donk, et al.
Published: (2022-04-01)

Spotlight on Amivantamab (JNJ-61186372) for EGFR Exon 20 Insertions Positive Non-Small Cell Lung Cancer
by: Brazel D, et al.
Published: (2021-12-01)

PEGylated thrombopoietin mimetic, JNJ‑26366821 a novel prophylactic radiation countermeasure for acute radiation injury
by: Gregory P. Holmes-Hampton, et al.
Published: (2023-09-01)

Dataset of eyeblink conditioning in mice treated with the selective mGluR1 antagonist JNJ16259685
by: Shoichi Tohyama, et al.
Published: (2023-04-01)

JNJ-64619178 radiosensitizes and suppresses fractionated ionizing radiation-induced neuroendocrine differentiation (NED) in prostate cancer
by: Jogendra Singh Pawar, et al.
Published: (2023-03-01)

INCIDENCE, MITIGATION, AND MANAGEMENT OF NEUROLOGIC ADVERSE EVENTS IN PATIENTS WITH MULTIPLE MYELOMA TREATED WITH CILTACABTAGENE AUTOLEUCEL (CILTA-CEL) IN CARTITUDE-2
by: H Einsele, et al.
Published: (2021-10-01)

Modelling the impact of JNJ-1802, a first-in-class dengue inhibitor blocking the NS3-NS4B interaction, on in-vitro DENV-2 dynamics
by: Clare P. McCormack, et al.
Published: (2023-12-01)

Modelling the impact of JNJ-1802, a first-in-class dengue inhibitor blocking the NS3-NS4B interaction, on in-vitro DENV-2 dynamics.
by: Clare P McCormack, et al.
Published: (2023-12-01)

Characterization of in vivo resistance to osimertinib and JNJ-61186372, an EGFR/Met bi-specific antibody, reveals unique and consensus mechanisms of resistance
by: Moores, Sheri L., et al.
Published: (2018)

Role of Anti-B-Cell Maturation Antigen (BCMA) in the Management of Multiple Myeloma
by: Ikhwan Rinaldi, et al.
Published: (2022-07-01)

P28 EFFICACY AND SAFETY OF CILTACABTAGENE AUTOLEUCEL (CILTA-CEL) IN PATIENTS WITH PROGRESSIVE MULTIPLE MYELOMA (MM) AFTER EXPOSURE TO NON-CELLULAR ANTI-B-CELL MATURATION ANTIGEN (BCMA) IMMUNOTHERAPY
by: N. van de Donk, et al.
Published: (2023-05-01)

Anti-seizure effects of JNJ-54175446 in the intra-amygdala kainic acid model of drug-resistant temporal lobe epilepsy in mice
by: Omar Mamad, et al.
Published: (2024-01-01)

The Effect of Clozapine and Novel Glutamate Modulator JNJ-46356479 on Nitrosative Stress in a Postnatal Murine Ketamine Model of Schizophrenia
by: Nina Treder, et al.
Published: (2023-01-01)

A Selective Histamine H4 Receptor Antagonist, JNJ7777120, Role on glutamate Transporter Activity in Chronic Depression
by: Yesim Yeni, et al.
Published: (2022-02-01)

Adverse effects, perceptions and attitudes related to BNT162b2, mRNA-1273 or JNJ-78436735 SARS-CoV-2 vaccines: Population-based cohort
by: Oliver Bürzle, et al.
Published: (2023-04-01)

CAR-T-Cell Therapy in Multiple Myeloma: B-Cell Maturation Antigen (BCMA) and Beyond
by: Abhinava K. Mishra, et al.
Published: (2023-11-01)

The Safety of mRNA-1273, BNT162b2 and JNJ-78436735 COVID-19 Vaccines: Safety Monitoring for Adverse Events Using Real-World Data
by: Soonok Sa, et al.
Published: (2022-02-01)

First‐in‐human study of JNJ‐63709178, a CD123/CD3 targeting antibody, in relapsed/refractory acute myeloid leukemia
by: Michael Boyiadzis, et al.
Published: (2023-03-01)

The Dual Cell Cycle Kinase Inhibitor JNJ-7706621 Reverses Resistance to CD37-Targeted Radioimmunotherapy in Activated B Cell Like Diffuse Large B Cell Lymphoma Cell Lines
by: Gro Elise Rødland, et al.
Published: (2019-11-01)

EFFICACY AND SAFETY OF CILTACABTAGENE AUTOLEUCEL (CILTA-CEL), A BCMA-DIRECTED CAR-T CELL THERAPY, IN PATIENTS WITH PROGRESSIVE MULTIPLE MYELOMA (MM) AFTER 1–3 PRIOR LINES OF THERAPY: CARTITUDE-2 PHASE 2 STUDY
by: ME Agha, et al.
Published: (2021-10-01)

The CSF-1-receptor inhibitor, JNJ-40346527 (PRV-6527), reduced inflammatory macrophage recruitment to the intestinal mucosa and suppressed murine T cell mediated colitis.
by: Carl L Manthey, et al.
Published: (2019-01-01)

P08: CARTITUDE-2 UPDATE: CILTACABTAGENE AUTOLEUCEL, A B-CELL MATURATION ANTIGEN–DIRECTED CHIMERIC ANTIGEN RECEPTOR T-CELL THERAPY, IN LENALIDOMIDE-REFRACTORY PATIENTS WITH PROGRESSIVE MULTIPLE MYELOMA AFTER 1-3 PRIOR LINES OF THERAPY
by: H Einsele, et al.
Published: (2022-04-01)

Comparative effectiveness of ciltacabtagene autoleucel in CARTITUDE‐1 versus physician's choice of therapy in the Flatiron Health multiple myeloma cohort registry for the treatment of patients with relapsed or refractory multiple myeloma
by: Thomas Martin, et al.
Published: (2022-02-01)

Evaluation of JNJ-54717793 a Novel Brain Penetrant Selective Orexin 1 Receptor Antagonist in Two Rat Models of Panic Attack Provocation
by: Pascal Bonaventure, et al.
Published: (2017-06-01)

Neurotoxic/Neuroprotective Effects of Clozapine and the Positive Allosteric Modulator of mGluR2 JNJ-46356479 in Human Neuroblastoma Cell Cultures
by: Patricia Gassó, et al.
Published: (2023-01-01)

Characterization of concurrent target suppression by JNJ-61178104, a bispecific antibody against human tumor necrosis factor and interleukin-17A
by: Songmao Zheng, et al.
Published: (2020-01-01)

Virology analysis in HCV genotype 1-infected patients treated with the combination of simeprevir and TMC647055/ritonavir, with and without ribavirin, and JNJ-56914845
by: Leen Vijgen, et al.
Published: (2017-05-01)

Protection of radiation-induced damage to the hematopoietic system, small intestine and salivary glands in rats by JNJ7777120 compound, a histamine H4 ligand.
by: Diego J Martinel Lamas, et al.
Published: (2013-01-01)

P971: ADJUSTED COMPARISON OF PATIENT REPORTED OUTCOMES FROM CARTITUDE-1 AND LOCOMMOTION COMPARING CILTACABTAGENE AUTOLEUCEL VERSUS REAL WORLD CLINICAL PRACTICE IN TRIPLE-CLASS EXPOSED MULTIPLE MYELOMA
by: K. Weisel, et al.
Published: (2022-06-01)

Anti-BCMA chimeric antigen receptors with fully human heavy-chain-only antigen recognition domains
by: Norris Lam, et al.
Published: (2020-01-01)

Pharmacodynamics of atabecestat (JNJ-54861911), an oral BACE1 inhibitor in patients with early Alzheimer’s disease: randomized, double-blind, placebo-controlled study
by: Maarten Timmers, et al.
Published: (2018-08-01)

Focus on JNJ-Q2, a novel fluoroquinolone, for the management of community-acquired bacterial pneumonia and acute bacterial skin and skin structure infections
by: Jones TM, et al.
Published: (2016-06-01)